Venture Visionary Partners LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Venture Visionary Partners LLC acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,922 shares of the company’s stock, valued at approximately $238,000.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares during the period. Renaissance Technologies LLC grew its holdings in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC increased its position in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Hims & Hers Health by 67.5% during the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares during the last quarter. Finally, M&G Plc bought a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $8,232,000. 63.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total value of $47,738.99. Following the sale, the insider now owns 172,274 shares of the company’s stock, valued at approximately $3,516,112.34. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 841,076 shares of company stock valued at $14,759,219 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Trading Down 9.4 %

NYSE:HIMS opened at $21.38 on Thursday. The stock has a market capitalization of $4.59 billion, a P/E ratio of 272.91 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a 50 day moving average of $17.24 and a 200-day moving average of $17.73.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. The business’s revenue was up 51.8% on a year-over-year basis. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Piper Sandler restated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.